Table 3. Association between OPG polymorphisms and the risk to develop cerebrovascular events in anti-CCP negative RA patients.
| SNP | Genotype/Allele | HR (95%CI) | p * |
| rs3134063 | TT | 1 (reference) | - |
| CT | 0.61 (0.21–1.76) | 0.362 | |
| CC | 0.14 (0.02–1.23) | 0.077 | |
| T | 1 (reference) | - | |
| C | 0.52 (0.26–1.06) | 0.072 | |
| rs2073618 | CC | 1 (reference) | - |
| CG | 0.60 (0.20–1.82) | 0.368 | |
| GG | 0.17 (0.03–0.89) | 0.035 | |
| C | 1 (reference) | - | |
| G | 0.45 (0.22–0.91) | 0.025 | |
| rs3134069 | AA | 1 (reference) | - |
| AC | 1.20 (0.26–5.64) | 0.814 | |
| CC | - | - | |
| A | 1 (reference) | - | |
| C | 1.18 (0.27–5.09) | 0.823 |
CCP: cyclic citrullinated protein/peptide antibodies; CI: confidence interval; HR: hazard ratios; RA: rheumatoid arthritis.
*Adjusted for sex, age at RA diagnosis and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking habit).